Compare MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MONDELEZ INTERNATIONAL INC Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? MONDELEZ INTERNATIONAL INC Common Stock trades at $60.41 (market cap $77.43B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 7.7× State Street SPDR S&P Biotech ETF's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.43% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold MONDELEZ INTERNATIONAL INC Common Stock for 107 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| MDLZ | XBI | |
|---|---|---|
Market Cap | $77.43B | $10.11B |
Volume | 7,695,104 | 12,903,266 |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $64.99 | $169.55 |
52-Week Low | $51.51 | $104.99 |
Typical Hold Time | 107 Days | 38 Days |
Enterprise Value | $97.78B | — |
Dividend Yield | 3.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mondelez International (MDLZ) trades at $60.67, up 2.17% with a bullish technical signal and strong analyst support. The stock shows consistent earnings beats, with Q2 2026 EPS of $0.73 exceeding expectations. Revenue growth continues, reaching $38.54B in 2025, while maintaining solid profitability with 8.86% net margin. Recent dividend increase to $0.52 per share and positive news coverage highlight management's confidence in sustained performance.
MDLZ presents a compelling investment case with 76% analyst buy ratings and $70.29 consensus target, offering 16% upside. The company's global brand strength and emerging market momentum support growth, though cocoa cost pressures and competitive snack market pose risks. Cash flow stability and shareholder returns through dividends provide defensive characteristics in uncertain markets.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
